Retatrutide represents the next conceptual step in a research progression that began with single-receptor incretin agonists and advanced through dual agonism.
Building on dual agonism
Once dual GIP/GLP-1 agonism was established as a research direction, investigators asked whether adding a third pathway — glucagon-receptor activity — would broaden the metabolic signaling studied in models. Retatrutide emerged as a synthetic peptide engineered to engage all three receptors at once.
Why the third receptor matters
Adding glucagon activity is the defining variable that separates retatrutide from earlier compounds, making it a frequent comparator against dual agonists — see retatrutide vs tirzepatide. For the underlying biology, see the incretin receptors explained and its mechanism of action.
Product page: Retatrutide research vials.
Research Use Only. Supplied strictly for laboratory research and development — not for human or veterinary use, consumption, or any therapeutic or diagnostic purpose. This article is research education, not usage guidance.